PL3523283T3 - Postacie krystaliczne i postacie soli związków stanowiących agonistów ppar - Google Patents
Postacie krystaliczne i postacie soli związków stanowiących agonistów pparInfo
- Publication number
- PL3523283T3 PL3523283T3 PL17787774T PL17787774T PL3523283T3 PL 3523283 T3 PL3523283 T3 PL 3523283T3 PL 17787774 T PL17787774 T PL 17787774T PL 17787774 T PL17787774 T PL 17787774T PL 3523283 T3 PL3523283 T3 PL 3523283T3
- Authority
- PL
- Poland
- Prior art keywords
- crystalline
- salt forms
- agonist compounds
- ppar agonist
- ppar
- Prior art date
Links
- 101150014691 PPARA gene Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 150000003839 salts Chemical group 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404474P | 2016-10-05 | 2016-10-05 | |
| EP17787774.3A EP3523283B1 (en) | 2016-10-05 | 2017-10-05 | Crystalline and salt forms of ppar agonist compounds |
| PCT/US2017/055403 WO2018067860A1 (en) | 2016-10-05 | 2017-10-05 | Crystalline and salt forms of ppar agonist compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3523283T3 true PL3523283T3 (pl) | 2021-12-13 |
Family
ID=60153508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17787774T PL3523283T3 (pl) | 2016-10-05 | 2017-10-05 | Postacie krystaliczne i postacie soli związków stanowiących agonistów ppar |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US10927094B2 (pl) |
| EP (1) | EP3523283B1 (pl) |
| JP (1) | JP7017563B2 (pl) |
| KR (1) | KR20190057129A (pl) |
| CN (1) | CN109843857B (pl) |
| AU (1) | AU2017340763B2 (pl) |
| CA (1) | CA3036587A1 (pl) |
| CO (1) | CO2019003162A2 (pl) |
| CY (1) | CY1124655T1 (pl) |
| DK (1) | DK3523283T3 (pl) |
| ES (1) | ES2887008T3 (pl) |
| HR (1) | HRP20211341T1 (pl) |
| HU (1) | HUE055678T2 (pl) |
| IL (1) | IL265730B (pl) |
| JO (1) | JOP20190039B1 (pl) |
| LT (1) | LT3523283T (pl) |
| MA (1) | MA46460A (pl) |
| MX (1) | MX385973B (pl) |
| MY (1) | MY202008A (pl) |
| PH (1) | PH12019500727A1 (pl) |
| PL (1) | PL3523283T3 (pl) |
| PT (1) | PT3523283T (pl) |
| RS (1) | RS62245B1 (pl) |
| RU (1) | RU2759724C2 (pl) |
| SG (1) | SG11201901995TA (pl) |
| SI (1) | SI3523283T1 (pl) |
| TW (1) | TWI769182B (pl) |
| UA (1) | UA124770C2 (pl) |
| WO (1) | WO2018067860A1 (pl) |
| ZA (1) | ZA201901744B (pl) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1888548E (pt) | 2005-05-26 | 2012-10-30 | Neuron Systems Inc | Derivado de quinolina para o tratamento de doenças da retina |
| JP5885670B2 (ja) | 2009-12-11 | 2016-03-15 | アルデイラ セラピューティクス， インコーポレイテッド | 黄斑変性の処置のための組成物および方法 |
| JP6514114B2 (ja) | 2013-01-23 | 2019-05-15 | アルデイラ セラピューティクス， インコーポレイテッド | 毒性アルデヒド関連疾患および処置 |
| WO2017035077A1 (en) | 2015-08-21 | 2017-03-02 | Aldeyra Therapeutics, Inc. | Deuterated compounds and uses thereof |
| WO2017062468A1 (en) * | 2015-10-07 | 2017-04-13 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| US10927094B2 (en) | 2016-10-05 | 2021-02-23 | Mitobridge, Inc. | Crystalline and salt forms of PPAR agonist compounds |
| EP3694500A4 (en) | 2017-10-10 | 2021-06-30 | Aldeyra Therapeutics, Inc. | TREATMENT OF INFLAMMATORY DISORDERS |
| US12006298B2 (en) | 2018-08-06 | 2024-06-11 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| EP3871667A4 (en) * | 2018-10-23 | 2022-08-17 | Japan Science and Technology Agency | PPAR DELTA ACTIVATOR |
| EP3962894A4 (en) | 2019-05-02 | 2023-01-11 | Aldeyra Therapeutics, Inc. | POLYMORPHIC COMPOUNDS AND USES THEREOF |
| US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| EP4149470A4 (en) | 2020-05-13 | 2024-04-24 | Aldeyra Therapeutics, Inc. | Pharmaceutical formulations and uses thereof |
| JP2024521353A (ja) | 2021-06-02 | 2024-05-31 | アステラス製薬株式会社 | Ｐｐａｒアゴニスト化合物の使用法およびその薬学的組成物 |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
| WO2025207099A1 (en) * | 2024-03-28 | 2025-10-02 | Astellas Pharma Inc. | Ppar-delta inhibitors for preventing post-operative atrial fibrillation |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003296404A1 (en) | 2003-01-06 | 2004-08-10 | Eli Lilly And Company | Heterocyclic ppar modulators |
| EP1671633A1 (en) | 2004-12-17 | 2006-06-21 | Sanofi-Aventis Deutschland GmbH | Use of PPAR agonists for the treatment of congestive heart failure |
| RU2007132973A (ru) | 2005-02-03 | 2009-03-10 | Айрм Ллк (Bm) | Соединения и композиции в качестве модуляторов ppar |
| CN101296892A (zh) * | 2005-09-07 | 2008-10-29 | 普莱希科公司 | Ppar活性化合物 |
| DE102006023336A1 (de) | 2006-05-18 | 2007-11-22 | Merck Patent Gmbh | 1,5-Diphenyl-pyrazole II |
| FR2940289B1 (fr) | 2008-12-23 | 2014-09-12 | Biopharmed | Derives de la classe des hydroxyquinoleines aminees pour le traitement du cancer du pancreas |
| CN102727489A (zh) * | 2012-07-18 | 2012-10-17 | 西南大学 | 5-芳(杂环)亚甲基噻唑烷-2，4-二酮在制备ppar激动剂中的应用 |
| US20170305894A1 (en) * | 2014-10-08 | 2017-10-26 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| WO2017062468A1 (en) * | 2015-10-07 | 2017-04-13 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| JP6925367B2 (ja) | 2016-04-13 | 2021-08-25 | ミトブリッジ，インコーポレーテッド | Ｐｐａｒアゴニスト、化合物、医薬組成物、及びその使用方法 |
| CN109789117B (zh) | 2016-10-05 | 2022-08-23 | 米托布里奇公司 | 治疗急性肾损伤的方法 |
| US10927094B2 (en) | 2016-10-05 | 2021-02-23 | Mitobridge, Inc. | Crystalline and salt forms of PPAR agonist compounds |
-
2017
- 2017-10-05 US US16/334,746 patent/US10927094B2/en active Active
- 2017-10-05 SG SG11201901995TA patent/SG11201901995TA/en unknown
- 2017-10-05 TW TW106134298A patent/TWI769182B/zh active
- 2017-10-05 PL PL17787774T patent/PL3523283T3/pl unknown
- 2017-10-05 JP JP2019518286A patent/JP7017563B2/ja active Active
- 2017-10-05 RU RU2019110736A patent/RU2759724C2/ru active
- 2017-10-05 KR KR1020197012668A patent/KR20190057129A/ko not_active Ceased
- 2017-10-05 WO PCT/US2017/055403 patent/WO2018067860A1/en not_active Ceased
- 2017-10-05 SI SI201730879T patent/SI3523283T1/sl unknown
- 2017-10-05 MA MA046460A patent/MA46460A/fr unknown
- 2017-10-05 IL IL265730A patent/IL265730B/en unknown
- 2017-10-05 UA UAA201903678A patent/UA124770C2/uk unknown
- 2017-10-05 AU AU2017340763A patent/AU2017340763B2/en active Active
- 2017-10-05 PT PT177877743T patent/PT3523283T/pt unknown
- 2017-10-05 MX MX2019003945A patent/MX385973B/es unknown
- 2017-10-05 MY MYPI2019001560A patent/MY202008A/en unknown
- 2017-10-05 LT LTEPPCT/US2017/055403T patent/LT3523283T/lt unknown
- 2017-10-05 DK DK17787774.3T patent/DK3523283T3/da active
- 2017-10-05 JO JOP/2019/0039A patent/JOP20190039B1/ar active
- 2017-10-05 CN CN201780062034.5A patent/CN109843857B/zh active Active
- 2017-10-05 HU HUE17787774A patent/HUE055678T2/hu unknown
- 2017-10-05 ES ES17787774T patent/ES2887008T3/es active Active
- 2017-10-05 EP EP17787774.3A patent/EP3523283B1/en active Active
- 2017-10-05 HR HRP20211341TT patent/HRP20211341T1/hr unknown
- 2017-10-05 RS RS20211042A patent/RS62245B1/sr unknown
- 2017-10-05 CA CA3036587A patent/CA3036587A1/en active Pending
-
2019
- 2019-03-20 ZA ZA2019/01744A patent/ZA201901744B/en unknown
- 2019-03-29 CO CONC2019/0003162A patent/CO2019003162A2/es unknown
- 2019-04-03 PH PH12019500727A patent/PH12019500727A1/en unknown
-
2021
- 2021-02-19 US US17/179,604 patent/US11530192B2/en active Active
- 2021-08-31 CY CY20211100775T patent/CY1124655T1/el unknown
-
2022
- 2022-12-16 US US18/082,847 patent/US11912681B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL265730A (en) | Crystalline forms and salts of ppar agonist compounds | |
| IL254351A0 (en) | An acid addition salt of a trk inhibitory compound | |
| IL247143B (en) | A new use of agonistic compounds for the sigma-1 receptor | |
| SI3380554T2 (sl) | Kristalne oblike per-kloro-gama-ciklodekstrinov | |
| PT3560925T (pt) | Novo composto e sal farmaceuticamente aceitável deste | |
| PT3113773T (pt) | Formas cristalinas do grapiprant | |
| IL266003A (en) | Salts of indazole derivatives and their crystals | |
| SG10202101979TA (en) | Crystalline forms of c21h22ci2n4o2 | |
| PL3532457T3 (pl) | Postacie krystaliczne hydroksynorketaminy | |
| SI3529236T1 (sl) | Kristalinične oblike eravaciklina | |
| IL253479A0 (en) | Crystalline forms of efinconazole | |
| ZA201607107B (en) | Salts and polymorphs of a substituted imidazopyridinyl-aminopyridine compound | |
| IL274758A (en) | Crystalline forms of praquinostat | |
| IL246835A0 (en) | Improved process for the preparation of trazodone and its hydrochloride salt | |
| SG11202105355XA (en) | Crystalline salts of corydalmine | |
| SG11202009262VA (en) | Salts of compounds and crystals thereof | |
| IL263363A (en) | Polymorph of nintedanib | |
| IL270937A (en) | Crystalline forms of saltalicib | |
| ZA201901155B (en) | Salt and crystal of diaza-benzofluorane compound | |
| GB201621771D0 (en) | New salts of compounds and uses thereof | |
| HUP1600613A2 (en) | Crystalline forms of sacubitril hemicalcium salt | |
| GB201621528D0 (en) | Use of trpv1 agonist | |
| IL252162A0 (en) | Crystal forms of poly(adenosine diphosphate) ribose polymerase inhibitors |